Dec 18, 2009 | Laboratory News, Laboratory Pathology
Researchers say Mobidiag’s microarray-based diagnostic test technology looks promising
There’s a new DNA-based microarray platform that could speed identification of blood-borne pathogens. By allowing clinical laboratories to deliver test results in just 18 hours, use of this new microarray could improve early detection and management of sepsis patients.
In a study headed by Päivi Tissari, M.D., of the Division of Clinical Microbiology, Helsinki University Hospital Laboratory in Finland, the Prove-it sepsis assay, manufactured by Helsinki-based Mobidiag, demonstrated 94.7% clinical sensitivity, 98.8% specificity, along with 100% sensitivity and specificity for methicillin-resistant Staphylococcus aureus bacteremia. The conventional process of growing a culture—the medical laboratory’s gold standard—typically takes between one to three days to become positive and two more days to identify the bacteria and their antibiotic sensitivity patterns. Mobidiag’s Prove-it sepsis assay returns results in only 18 hours.
(more…)
Oct 20, 2009 | Laboratory News, Laboratory Pathology
New diagnostic protocols that use lactic acid test cut deaths from sepsis
Laboratory testing plays a key role in a new diagnostic protocol for sepsis that is saving lives at hospitals operated by Methodist Le Bonheur Healthcare in Tennessee. Since implementation of this new sepsis protocol, patient outcomes have improved significantly.
Leadership at Methodist North Hospital (MNH) decided to adopt the protocol after reading a study by Emanuel Rivers, M.D., Ph.D., of Henry Ford Medical Center, published in the New England Journal of Medicine, that establishes criteria for identifying these patients.
(more…)
Apr 10, 2009 | Digital Pathology, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory News, Laboratory Operations, Laboratory Pathology
New diagnostic and treatment approach will require close interaction with Pathologists
There’s a novel diagnostic device designed to detect sepsis that also has to potential to engage the pathologist as part of the bedside care team. It is also an example of how nanotechnology and magnetism are being combined in ways that may support in vivo diagnosis and treatment.
Created by a research scientist at Children’s Hospital Boston, this new device uses magnetism to quickly pull disease pathogens out of infected blood. Experts predict it could become the first line of defense for sepsis, a disease which kills about 200,000 Americans each year.
The system works by drawing the patient’s blood and adding tiny magnetic beads, pre-coated with antibodies against specific pathogens, such as Candida albicans. The blood is run through a microfluidic system in which two liquid flow streams run side by side without mixing. One channel contains blood and the other contains a saline-based collection fluid. The beads bind to the pathogens. A magnet then pulls them, along with the pathogens, into the collection fluid. The collection fluid is ultimately discarded, and the cleansed blood reintroduced into the patient.
(more…)
